论文部分内容阅读
目的 探讨葛根素注射液辅助治疗对稳定性心绞痛患者心功能以及血管内皮功能的影响.方法 选取2018年1月—2018年12月入院治疗的稳定性心绞痛患者92 例,随机数表法将所选患者分为对照组和实验组各46 例.对照组予以常规西药方案治疗:酒石酸美托洛尔片50 mg,bid;阿司匹林肠溶片口服100 mg,qd;瑞舒伐他汀10 mg,qd.实验组在常规西药方案治疗基础上加用葛根素注射液辅助治疗.两组疗程均为8 周,比较治疗前后两组患者临床总有效率,心功能指标变化及血管内皮功能指标变化.结果 治疗后,实验组总有效率89.1%,显著高于对照组的78.3%,差异具有统计学意义(P＜0.05);实验组左心室收缩末期内径(LVESD)及左心室舒张末期内径(LVEDD)分别显著低于对照组,左心室射血分数(LVEF)显著高于对照组(P＜0.05).治疗后实验组血浆ET-1浓度为(103.01±12.99)ng/L,显著低于对照组的(118.84±14.69)ng/L,差异具有统计学意义(P＜0.05),实验组血浆NO水平为(77.58±5.97)μmol/L,显著高于对照组的(52.00±5.12)μmol/L,差异具有统计学意义(P＜0.05).结论 葛根素注射液辅助治疗可显著提高临床治疗有效率,改善稳定性心绞痛患者心功能、血管内皮功能,显著改善患者的临床症状.“,”Objective To investigate the effect of puerarin injection on cardiac function and vascular endothelial function in patients with stable angina pectoris. Methods 92 patients with stable angina pectoris admitted to the Fourth Affiliated Hospital of China Medical University from January 2018 to December 2018 were selected. The selected patients were divided into control group and experimental group by random number table method. There were 46 patients in the control group and 46 patients in the experimental group. The control group was treated with conventional Western medicine regimen: metoprolol tartrate tablets 50 mg, bid; aspirin enteric-coated tablets 100 mg, qd; rosuvastatin 10 mg, qd. The experimental group was treated with puerarin injection on the basis of conventional Western medicine. Both groups were treated for 8 weeks. The clinical total effective rate, changes of cardiac function indexes and vascular endothelial function indexes of the two groups were compared before and after treatment. Results After treatment, the total effective rate of the experimental group was 89.1%, which was significantly higher than that of the control group (78.3%), and the difference was statistically significant (P＜0.05). Left ventricular end-systolic diameter (LVESD) and left ventricular end-diastolic diameter (LVEDD) in the experimental group were significantly lower than those in the control group, and left ventricular ejection fraction (LVEF) was significantly higher than that in the control group (P＜0.05). The plasma ET-1 concentration in the experimental group [(103.01±12.99) ng/L] was significantly lower than that in the control group [(118.84±14.69) ng/L], and the difference was statistically significant (P＜0.05). The plasma NO level in the experimental group [(77.58±5.97) mol/L] was significantly higher than that in the control group [(52.00±5.12) mol/L], and the difference was statistically significant (P＜0.05). Conclusion The adjuvant treatment of puerarin injection can significantly improve the efficiency of clinical treatment, improve the heart function and vascular endothelial function of patients with stable angina pectoris, and significantly improve the clinical symptoms of patients.